Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert A Antolin

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Plos Biology|October 20, 2021
AI delivers Michaelis constants as fuel for genome-scale metabolic modelsAlbert A Antolin, Marta Cascante
Expert Opinion on Drug Discovery|July 15, 2024
Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discoveryLeticia Manen-Freixa, Albert A Antolin
British Journal of Clinical Pharmacology|April 30, 2026
The interplay between molecular architecture, pharmacology, and suspected adverse drug reactions associated with nonsteroidal androgen antagonists in the United KingdomSimrit Dhillon, Albert A Antolin, Alan M Jones
Future Medicinal Chemistry|November 29, 2019
Public resources for chemical probes: the journey so far and the road aheadAlbert A Antolin, Paul Workman, Bissan Al-Lazikani
Current Pharmaceutical Design|September 28, 2016
Polypharmacology in Precision Oncology: Current Applications and Future ProspectsAlbert A Antolin, Paul Workman, Jordi Mestres, et al.
Cell Chemical Biology|October 5, 2023
A machine learning and live-cell imaging tool kit uncovers small molecules induced phospholipidosisHuabin Hu, Amelie Tjaden, Stefan Knapp, et al.
British Journal of Clinical Pharmacology|July 30, 2021
Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationaleDaranjit Sandhu, Albert A Antolin, Anthony R Cox, et al.
Cell Chemical Biology|June 2, 2021
Evolution of kinase polypharmacology across HSP90 drug discoveryAlbert A Antolin, Paul A Clarke, Ian Collins, et al.
European Journal of Medicinal Chemistry|January 31, 2026
Charting the evolving landscape of kinase hinge-binding chemotypes beyond flatland: a systematic analysis and opportunities for sp<sup>3</sup>-rich bindersShangde Liu, Tianlei Han, Zhenyu Zhang, et al.
Journal of Chemical Information and Modeling|September 18, 2024
Combining Data-Driven and Structure-Based Approaches in Designing Dual PARP1-BRD4 Inhibitors for Breast Cancer TreatmentBo Feng, Hui Yu, Xu Dong, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Plos Biology|October 20, 2021
AI delivers Michaelis constants as fuel for genome-scale metabolic modelsAlbert A Antolin, Marta Cascante
Expert Opinion on Drug Discovery|July 15, 2024
Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discoveryLeticia Manen-Freixa, Albert A Antolin
British Journal of Clinical Pharmacology|April 30, 2026
The interplay between molecular architecture, pharmacology, and suspected adverse drug reactions associated with nonsteroidal androgen antagonists in the United KingdomSimrit Dhillon, Albert A Antolin, Alan M Jones
Future Medicinal Chemistry|November 29, 2019
Public resources for chemical probes: the journey so far and the road aheadAlbert A Antolin, Paul Workman, Bissan Al-Lazikani
Current Pharmaceutical Design|September 28, 2016
Polypharmacology in Precision Oncology: Current Applications and Future ProspectsAlbert A Antolin, Paul Workman, Jordi Mestres, et al.
Cell Chemical Biology|October 5, 2023
A machine learning and live-cell imaging tool kit uncovers small molecules induced phospholipidosisHuabin Hu, Amelie Tjaden, Stefan Knapp, et al.
British Journal of Clinical Pharmacology|July 30, 2021
Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationaleDaranjit Sandhu, Albert A Antolin, Anthony R Cox, et al.
Cell Chemical Biology|June 2, 2021
Evolution of kinase polypharmacology across HSP90 drug discoveryAlbert A Antolin, Paul A Clarke, Ian Collins, et al.
European Journal of Medicinal Chemistry|January 31, 2026
Charting the evolving landscape of kinase hinge-binding chemotypes beyond flatland: a systematic analysis and opportunities for sp<sup>3</sup>-rich bindersShangde Liu, Tianlei Han, Zhenyu Zhang, et al.
Journal of Chemical Information and Modeling|September 18, 2024
Combining Data-Driven and Structure-Based Approaches in Designing Dual PARP1-BRD4 Inhibitors for Breast Cancer TreatmentBo Feng, Hui Yu, Xu Dong, et al.
Pageof 3